Laser Treatment for Lichen Sclerosus

Last updated: May 13, 2025
Sponsor: Sciton
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Fractional 2940 nm Laser

Clinical Study ID

NCT06389071
PLS001
  • Ages > 18
  • Female
  • Accepts Healthy Volunteers

Study Summary

Fractional ablative laser treatment for Lichen Sclerosus lesion

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Female aged 18 years or older

  • Biopsy-proven vulvar lichen sclerosus lesion

  • Experiencing one or more of the following symptoms of LS:

  1. Dryness

  2. Itching

  3. Burning

  4. Bleeding

  5. Blistering

  6. Soreness

  7. Easily bruises

  8. Easily tears

  9. Ulcerated lesions

  10. Painful intercourse

  • Negative urine pregnancy test if subject is of childbearing potential beforeenrollment

  • Absence of vulvovaginal infection i.e. fungi, bacterial vaginosis, and STI

  • Ability to understand and sign informed consent, questionnaires, and allinvestigation requirements

  • Willing to consent to clinical photographs of the treatment area

  • Willing to consent to ultrasound images of the treatment area

  • Willing and able to logistically follow schedule of treatments and follow-up visits

Exclusion

Exclusion Criteria:

  • Pregnancy, less than 3 months postpartum, or planning to become pregnant during theinvestigation to protect integrity of the data

  • Is a nursing mother

  • History of uncontrolled malignant disease

  • Active urogenital infection or chronic infection (i.e., candida, herpes, herpessimplex, bacterial vaginosis, trichomoniasis, or other infection)

  • Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich syndrome)

  • Subjects with genital skin disease, psoriasis due to risk of koeberizing

  • Subjects on immunosuppressants: mycophenolate, retinoids, azathioprine, cyclosporin

  • Known allergy or intolerance to local anesthesia

  • Known history of connective tissue disease

  • Known propensity for keloid formations

  • Known medical condition that may affect wound healing

  • Any reason that the investigator deems prohibits participation in the investigation

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Fractional 2940 nm Laser
Phase:
Study Start date:
March 01, 2024
Estimated Completion Date:
December 30, 2025

Connect with a study center

  • Clinique Medicale Uro-Gyneco de l'Abitibi

    Val-d'Or, Quebec J9P1W1
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.